HIV/AIDS Clinical Trials in Philadelphia

Showing 141-160 of 730 trials

Autologous CD4 T-Cells in HIV (C34-CXCR4)

NCT03020524

A single cohort, open-label pilot study of the safety and tolerability of a single infusion of autologous CD4+ T-cells genetically modified with an HR2, C34-peptide conjugated to the CXCR4 N-terminus using a lentiviral vector in HIV-infected subjects. This is a first in human study of C34-CXCR4 T cells

Hiv

University of Pennsylvania9 participantsStarted Jan 2017

Philadelphia, Pennsylvania, United States

COMPLETEDPhase 4< 1 mile

Integrase and Maraviroc Intensification in Neurocognitive Dysfunction (InMIND)

NCT02519777

People infected with HIV often have cognitive dysfunction even if they are on antiretroviral therapy (ART) and have undetectable viral loads. The study evaluated if the addition of maraviroc (MVC) and dolutegravir (DTG) (which are two antiretroviral \[ARV\] medications) to participants' existing ART regimens improved participants' neurocognitive performance.

HIV Infections

National Institute of Allergy and Infectious Diseases (NIAID)191 participantsStarted Apr 2016

Los Angeles, California, United States • San Diego, California, United States • Torrance, California, United States +27 more locations

Autologous CD4 T-Cells in HIV (C34-CXCR4)

Integrase and Maraviroc Intensification in Neurocognitive Dysfunction (InMIND)

HIV/AIDS Trials in Other Cities

An Observational Study of Long-term Outcomes of HIV-1 Infection in Persons Who Become HIV-1 Infected After Enrollment in HIV-1 Vaccine Trials

A Study of GSK1349572 Versus Raltegravir (RAL) With Investigator Selected Background Regimen in Antiretroviral-Experienced, Integrase Inhibitor-Naive Adults

Lenalidomide in Treating Patients With AIDS-Associated Kaposi's Sarcoma

Pharmacokinetic Study to Evaluate Double-Dose Levonorgestrel Emergency Contraception in Combination With Efavirenz-Based Antiretroviral Therapy or Rifampicin-Containing Anti-Tuberculosis Therapy

Safety, Tolerability and Efficacy on Low Density Lipoprotein Cholesterol (LDL-C) of Evolocumab in Participants With Human Immunodeficiency Virus (HIV) and Hyperlipidemia/Mixed Dyslipidemia

TH9507 Extension Study in Patients With HIV-Associated Lipodystrophy

A Crossover Study Evaluating 3 Non-medicated Silicone IVRs

Integrated Stepped Care for Unhealthy Alcohol Use in HIV

Randomized, Double-Blind, Placebo-Controlled Trial, Followed by Single-Arm Treatment of PRO 140

Safety of and Immune Response to a Prime-Boost Vaccine Regimen in HIV-Uninfected Vaccine-Naive Adults

Evaluating the Immunogenicity of the AIDSVAX B/E Vaccine and the MVA/HIV62B Vaccine in Healthy, HIV-1-Uninfected Adults Who Previously Received MVA/HIV62B in DNA/MVA or MVA/MVA Regimens in HVTN 205

Evaluating the Safety and Immunogenicity of HIV Clade C DNA Vaccine and MF59- or AS01B-Adjuvanted Clade C Env Protein Vaccines in Various Combinations in Healthy, HIV-Uninfected Adults

Evaluating the Safety and Pharmacokinetics of VRC01, VRC01LS, and VRC07-523LS, Potent Anti-HIV Neutralizing Monoclonal Antibodies, in HIV-1-Exposed Infants

Study of Dapivirine Vaginal Ring (VR) in Adolescents

Rectal Microbicide Acceptability, Tolerability and Adherence

Evaluating the Pharmacokinetics, Safety, and Tolerability of Doravirine (MK-1439) and Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (MK-1439A) in HIV-1-Infected Children and Adolescents

Evaluating the Safety and Pharmacokinetics of Maraviroc in HIV-1-Exposed Infants at Risk of Acquiring HIV-1 Infection

TMC114IFD3001 - Study Providing Continued Access to Treatment With Darunavir (DRV)/Ritonavir(Rtv) in HIV1 Infected Adults, Adolescents and Children Aged 3 Years or Above and Coming From Previous Company Sponsored Studies With DRV

Other Conditions in Philadelphia